SCHEMBL30516341

SCHEMBL30516341

CN1CCN(c2cccc3c2cc(C(F)(F)F)n3Cc2ccc(Cl)c(Cl)c2)CC1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CCR2 P41597 11/20 0.46
CYP1A2 P05177 2/20 0.40
CYP2D6 P10635 2/20 0.40
SIGMAR1 Q99720 2/20 0.40
TMEM97 Q5BJF2 1/20 0.40
SOS1 Q07889 1/20 0.40
DRD2 P14416 1/20 0.40
DRD3 P35462 1/20 0.40
ALDH1A1 P00352 1/20 0.38
LMNA P02545 1/20 0.38
CYP3A4 P08684 1/20 0.38
MAPT P10636 1/20 0.38
CYP2C9 P11712 1/20 0.38
HPGD P15428 1/20 0.38
CYP2C19 P33261 1/20 0.38
HTR1A P08908 1/20 0.38
HTR7 P34969 1/20 0.38
HTR6 P50406 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21291615 1.00 CCR2 (0.46) CCR2CYP1A2CYP2D6SIGMAR1TMEM97
SCHEMBL30516340 0.92 SOS1 (0.41) CCR2SOS1DRD2DRD3HTR1A
SCHEMBL21291586 0.92 SOS1 (0.41) CCR2SOS1DRD2DRD3HTR1A
SCHEMBL21291591 0.88 HTR6 (0.48) CYP1A2CYP2D6SIGMAR1DRD2ALDH1A1
SCHEMBL30516335 0.88 HTR6 (0.48) CYP1A2CYP2D6SIGMAR1DRD2ALDH1A1
SCHEMBL21291614 0.88 DRD3 (0.44) DRD2DRD3ALDH1A1CYP2C9HTR1A
SCHEMBL30516359 0.88 DRD3 (0.44) DRD2DRD3ALDH1A1CYP2C9HTR1A
Hydrochloric Acid SCHEMBL30516381 0.88 HTR6 (0.47) CYP1A2CYP2D6DRD2ALDH1A1CYP3A4
SCHEMBL21291618 0.86 SOS1 (0.38) SOS1DRD2ALDH1A1MAPTHTR1A
SCHEMBL30516346 0.86 SOS1 (0.38) SOS1DRD2ALDH1A1MAPTHTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12319682-B2 Indole and benzimidazole derivatives as dual 5-HT2A and 5-HT6 receptor antagonists ADAMED PHARMA S.A. (PL) 2025-06-03 US claimed
CN-112041300-B Indole and benzimidazole derivatives as dual 5-HT2A and 5-HT6 receptor antagonists 阿达梅德制药公司 2023-07-28 CN claimed
US-12319682-B2 Indole and benzimidazole derivatives as dual 5-HT2A and 5-HT6 receptor antagonists ADAMED PHARMA S.A. (PL) 2025-06-03 US disclosed
US-20240287056-A1 INDOLE AND BENZIMIDAZOLE DERIVATIVES AS DUAL 5-HT 2A AND 5-HT6 RECEPTOR ANTAGONISTS Adamed Pharma S.A (PL) 2024-08-29 US disclosed
US-11981668-B2 Indole and benzimidazole derivatives as dual 5-HT2A and 5-HT6 receptor antagonists ADAMED PHARMA S.A. (PL) 2024-05-14 US disclosed
CN-112041300-B Indole and benzimidazole derivatives as dual 5-HT2A and 5-HT6 receptor antagonists 阿达梅德制药公司 2023-07-28 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12319682-B2 Indole and benzimidazole derivatives as dual 5-HT2A and 5-HT6 receptor antagonists HTR2A, HTR6, HTR2C CCR2 2143/4885CYP1A2 157/4885CYP2D6 82/4885
US-11981668-B2 Indole and benzimidazole derivatives as dual 5-HT2A and 5-HT6 receptor antagonists HTR2A, HTR2C, HTR6 CCR2 1238/4885CYP1A2 169/4885CYP2D6 99/4885
US-20240287056-A1 INDOLE AND BENZIMIDAZOLE DERIVATIVES AS DUAL 5-HT 2A AND 5-HT6 RECEPTOR ANTAGONISTS HTR2A, HTR6, HTR2C CCR2 1921/4885CYP1A2 151/4885CYP2D6 78/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.